00882 TIANJIN DEV
- 1.910
- -0.010-0.52%
TIANJIN DEV News
Tianjin Development Renews Service Contracts With Associate
Tianjin dev: Tianjin Lisheng Pharmaceutical's net income attributable to the parent company in the first three quarters decreased by 50.6% to 0.169 billion yuan.
Tianjin dev (00882) announced that tianjin lisheng pharmaceutical, an indirectly wholly-owned subsidiary, achieved total operating income of 1.024 billion yuan (RMB, the same below) for the nine months ended September 30, 2024, a year-on-year increase of 12.3%; net income attributable to the owners of the parent company was 0.169 billion yuan, a year-on-year decrease of 50.6%; and basic earnings per share was 0.66 yuan.
Tianjin DEV (00882): Tianjin Lisheng Pharmaceutical's net income attributable to mother for the first three quarters was 0.169 billion yuan.
tianjin dev (00882) announced that its indirect non-wholly-owned subsidiary tianjin lisheng pharmaceutical as at 3 September 2024...
TIANJIN DEV: Unaudited Financial Results for the nine months ended 30 September 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Tianjin Lisheng Invests 210 Million Yuan in China Bohai Bank's Structured Deposit
tianjin dev (00882.HK) subsidiary subscribed 0.21 billion yuan for another structured deposit.
Grill Lockmate September 26th Tianjin Dev (00882.HK) announced that due to the expiration of the previous structured deposits, on September 26, 2024, the company's indirectly controlled non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed a third CBHB wealth management agreement, subscribing to another structured deposit with a principal amount of RMB 0.21 billion.
TIANJIN DEV: 2024 Interim Report
Tianjin Development Holdings Books Lower Profit, Revenue in H1
TIANJIN DEV To Go Ex-Dividend On September 23rd, 2024 With 0.0518 HKD Dividend Per Share
August 29th (Beijing Time) - $TIANJIN DEV(00882.HK)$ is trading ex-dividend on September 23rd, 2024.Shareholders of record on September 24th, 2024 will receive 0.0518 HKD dividend per share on
tianjin dev (00882.HK) has a net profit of approximately 0.288 billion Hong Kong dollars for the interim period, with an interim dividend of 5.18 Hong Kong cents.
Great Connection August 29th, Tianjin Dev (00882.HK) announced that for the six months ended June 30, 2024, the company's income was approximately HK$1,820,260,000 (same period last year: HK$1,830,477,000). The attributable profit to owners of the company was approximately HK$288,077,000 (same period last year: HK$371,509,000). Basic earnings per share were 26.85 HK cents, with an interim dividend of 5.18 HK cents per share (same period last year: 3.45 HK cents per share).
TIANJIN DEV: Announcement of Interim Results for the six months ended 30 June 2024
Tianjin Lisheng Pharmaceutical's H1 Attributable Profit, Revenue Grow
Tianjin Dev (00882.HK): Tianjin Lisheng Pharmaceutical's net income in the first half of the year was 0.102 billion yuan, a year-on-year increase of 13.50%.
Tianjin Development (00882.HK) announced that Tianjin Lisheng Pharmaceutical (002393.SZ) achieved revenue of 0.745 billion yuan (RMB) in the first half of 2024, a year-on-year growth of 13.25%; the net income attributable to Lisheng Pharmaceutical shareholders was 0.102 billion yuan, a year-on-year growth of 13.50%; the basic earnings per share was 0.40 yuan.
TIANJIN DEV: Unaudited Financial Results for the six months ended 30 June 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
Board of directors of Tianjin Dev (00882.HK) held a meeting on August 29 to consider and approve the mid-term performance.
Tianjin Dev (00882.HK) announced that it will hold a board of directors meeting on Thursday, August 29, 2024 to consider and approve, among other matters, the announcement of the Company and its subsidiaries' interim results for the six months ended June 30, 2024, and to consider the distribution of interim dividends (if any).
TIANJIN DEV: Date of Board Meeting
Geely Auto's net income doubled YoY in the first quarter; Xinyi Solar expects a mid-term profit increase of about 40%.
Longfor Group has repurchased a total principal amount of approximately USD 403 million of 3.95% preferred notes; Tencent has spent HKD 1.001 billion to repurchase 2.68 million shares at a repurchase price of HKD 371-375.6 per share.
Tianjin Development (00882.HK) subsidiary intends to sell 24.65% equity of Tianjin Tianbian Pharmaceutical for 120 million yuan.
On June 28, Gelonhui reported that Tianjin Dev (00882.HK) announced the sale of 24.65% equity in Tianjin Tianbian Pharmaceutical Co., Ltd. On June 28, 2024, Tianjin Lisheng Pharmaceutical and the final winning bidder, Grandpharma (China), entered into a property transaction contract for the sale of the shares at a total price of 120 million yuan. After the completion of the sale, the Group will no longer hold any equity in Tianjin Tianbian. Tianjin Tianbian is a limited liability company established in China, mainly engaged in the production, processing, sales of Chinese and Western medicines, chemical drugs, active pharmaceutical ingredients, trial drugs, biological pharmaceuticals, related services, and the provision of medical information consulting.
TIANJIN DEV To Go Ex-Dividend On June 20th, 2024 With 0.088 HKD Dividend Per Share
June 20th (Beijing Time) - $TIANJIN DEV(00882.HK)$ is trading ex-dividend on June 20th, 2024.Shareholders of record on June 21st, 2024 will receive 0.088 HKD dividend per share on July 29th, 2024. The
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product
Analysis
Price Target
No Data
No Data